STOCK TITAN

Evaxion AS Stock Price, News & Analysis

EVAX Nasdaq

Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.

Evaxion Biotech A/S (EVAX) is a clinical-stage biotechnology company leveraging proprietary AI platforms to advance immunotherapies for cancer and infectious diseases. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.

Investors and industry observers will find timely updates on clinical trial progress, regulatory filings, and technology innovations. Our curated collection includes press releases on AI-driven drug discovery, partnership announcements, and financial reports, all organized for efficient tracking of the company's trajectory.

Key content areas include updates from Evaxion's PIONEER and EDEN platform pipelines, oncology vaccine developments, and infectious disease research breakthroughs. The repository is maintained to reflect the company's evolving position at the intersection of artificial intelligence and immunotherapy.

Bookmark this page for streamlined access to Evaxion's official communications. Check regularly for new developments in personalized cancer vaccines and AI-optimized antigen discovery.

Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) reported significant advancements in its immunotherapy programs during Q2 2022, including the expansion into non-small cell lung cancer and production of personalized cancer treatments for melanoma. The company identified gonorrhea as its second bacterial product target. Despite a net loss of $4.8 million and cash reserves of $25.3 million, Evaxion anticipates these funds will support development efforts for the next year. Plans to initiate a Phase 2b trial in partnership with Merck's KEYTRUDA® are also highlighted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announces significant executive changes, with Lars Staal Wegner resigning as CEO but staying on as an advisor. Per Norlén, M.D., Ph.D., with over 20 years in clinical drug development, has been appointed as the new CEO. Norlén's experience in oncology and leadership at biopharmaceutical companies is expected to strengthen Evaxion's management as they pursue new partnerships and consolidate future projects. Chair Marianne Soegaard expressed confidence in Norlén's ability to enhance the company's growth and benefit stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
management
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology firm, will announce its Q2 2022 financial results on August 10 at 8:30 a.m. EDT. The presentation will showcase the company’s progress in developing AI-driven immunotherapies for various diseases. Investors can join the call via US dial-in at +1-844-825-9789 or internationally at +1-412-317-5180 using Conference ID 10169785. An audio webcast will also be available on Evaxion’s events page.

Evaxion is based in Hørsholm, Denmark, employing around 70 staff and holding a diverse pipeline of immunotherapy candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) has identified Gonorrhea as its second target for the EVX-B2 vaccine product candidate, following positive pre-clinical findings. The company's AI platform, EDEN, has pinpointed promising antigen candidates, addressing a significant unmet medical need. Gonorrhea poses serious health risks, with the CDC reporting 1.14 million new infections annually in the U.S., including 550,000 drug-resistant cases. Evaxion aims to provide a prophylactic vaccine to produce antibodies against this infection, potentially improving public health outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
none
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced the selection of EVX-03 as a product candidate within its DNA technology platform to target non-small cell lung cancer (NSCLC). The company plans to file for regulatory approval in H2 2022 based on positive pre-clinical results showing significant tumor reduction and a dose-response relationship. The NSCLC market is currently valued at $23 billion and projected to reach $33 billion by 2029. EVX-02 is also in the pipeline, with a phase 1/2a trial expected to read out in Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced a committed equity purchase agreement with Lincoln Park Capital Fund for up to $40 million in American Depositary Shares (ADSs) over 36 months. This agreement allows Evaxion flexibility in deciding the timing and amount of sales, thereby enhancing its financial position amid market uncertainties. As of Q1 2022, Evaxion had cash and equivalents of $31.4 million, sufficient for operations for at least 12 months without the agreement. The company is focused on advancing its personalized cancer medicines in Phase 2 clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
none
Rhea-AI Summary

Inversago Pharma has appointed Glenn S. Vraniak as its new Chief Financial Officer, effective immediately. With over 20 years of experience in the life sciences sector, Vraniak previously served as CFO at Evaxion Biotech, where he led the company through a successful IPO on Nasdaq in February 2021. His extensive background includes roles at electroCore and GE Capital. CEO François Ravenelle welcomed him, anticipating his impact on Inversago's growth, particularly in developing therapies for metabolic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
management
-
Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) announced regulatory clearance for a Phase 2b trial of EVX-01 targeting metastatic melanoma and completed recruitment for its Phase 1/2a trial of EVX-02. The company ended Q1 2022 with $31.4 million in cash and equivalents, a slight decrease from $32.2 million at the end of 2021. R&D expenses rose to $4.8 million, while the net loss was $5.8 million, compared to $4.1 million in Q1 2021. Evaxion is optimistic about advancing its cancer therapies and exploring partnerships in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.11%
Tags
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced successful production of personalized cancer immunotherapies for all patients in its Phase 1/2a trial of EVX-02 for adjuvant melanoma. The team confirmed the feasibility of its complex production chain within a critical timeframe. The trial, involving 16 fully resected patients in Australia, aims to prevent disease relapse using AI-driven, DNA-based immunotherapies. This achievement strengthens Evaxion's capabilities for larger trials exploring clinical benefits, bolstering investor confidence in its AI-immunology platform and the future of personalized cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) will present its first-quarter 2022 financial results on May 11 at 8:30 a.m. EDT. For those wishing to join the conference call, the US dial-in number is 1-877-407-0792 and the international number is 1-201-689-8263, using Conference ID 13729241. The event can also be accessed via a webcast on Evaxion's website. Evaxion is a clinical-stage biotechnology company focused on AI-driven immunotherapies for treating cancer and infectious diseases. Their pipeline includes three patient-specific cancer immunotherapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
conferences

FAQ

What is the current stock price of Evaxion AS (EVAX)?

The current stock price of Evaxion AS (EVAX) is $2.66 as of July 11, 2025.

What is the market cap of Evaxion AS (EVAX)?

The market cap of Evaxion AS (EVAX) is approximately 15.1M.
Evaxion AS

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

15.10M
4.86M
5.61%
0.86%
1.38%
Biotechnology
Healthcare
Link
Denmark
Horsholm